Translational development of an ADAMTS-5 antibody for osteoarthritis disease modification

Autor: Larkin, J. ^{†, ‡}, Lohr, T.A. ^{†, ‡}, Elefante, L. ^‡, Shearin, J. ^§, Matico, R. ^§, Su, J.-L. ^§, Xue, Y. ^‡, Liu, F. ^‖, Genell, C. ^¶, Miller, R.E. ^#, Tran, P.B. ^#, Malfait, A.-M. ^#, Maier, C.C. ^¶, Matheny, C.J. ^††

Publikováno v: In Osteoarthritis and Cartilage August 2015 23(8):1254-1266

The highs and lows of translational drug development: antibody-mediated inhibition of ADAMTS-5 for osteoarthritis disease modification

Autor: Larkin, J., Lohr, T., Elefante, L., Shearin, J., Matico, R., Su, J-L., Xue, Y., Liu, F., Rossman, E.I., Renninger, J., Wu, X., Abberley, L., Miller, R.E., Foulcer, S., Chaudhary, K.W., Genell, C., Murphy, D., Tran, P.B., Apte, S., Malfait, A-M., Maier, C.C., Matheny, C.J.

Publikováno v: In Osteoarthritis and Cartilage April 2014 22 Supplement:S483-S484

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Atiprimod (SK&F 106615), a novel macrophage targeting agent, enhances alveolar macrophage candidacidal activity and is not immunosuppressive in Candida-infected mice.

Autor: Badger AM; Department of Bone and Cartilage Biology, Smith Kline Beecham Pharmaceuticals Research and Development, King of Prussia, PA 19406-0939, USA., Handler JA, Genell CA, Herzyk D, Gore E, Polsky R, Webb L, Bugelski PJ

Publikováno v: International journal of immunopharmacology [Int J Immunopharmacol] 1999 Mar; Vol. 21 (3), pp. 161-76.